Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

被引：52

作者：

Muralidharan, G

Fruncillo, RJ

Micalizzi, M

Raible, DG

Troy, SM

机构：

[1] Wyeth Ayerst Res, Dept Clin Pharmacol, Collegeville, PA 19426 USA

[2] Wyeth Ayerst Res, Clin Pharmacol Unit, Philadelphia, PA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 04期

关键词：

D O I：

10.1128/AAC.49.4.1656-1659.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The pharmacokinetics of tigecycline was evaluated in 46 healthy young and elderly men and women. Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters. Based on pharmacokinetics, no dosage adjustment is warranted based on age or sex.

引用

收藏

页码：1656 / 1659

页数：4

相关论文

共 26 条

[1] In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain [J].

Betriu, C ;

Rodríguez-Avial, I ;

Sánchez, BA ;

Gómez, M ;

Alvarez, J ;

Picazo, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :892-895

[2] In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae:: Mechanisms of macrolide and tetracycline resistance [J].

Betriu, C ;

Culebras, E ;

Rodríguez-Avial, I ;

Gómez, M ;

Sánchez, BA ;

Picazo, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :323-325

[3] In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases [J].

Biedenbach, DJ ;

Beach, ML ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) :173-177

[4] Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections [J].

Cazzola, M ;

Blasi, F ;

Centanni, S ;

Donner, CF ;

Allegra, L .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (05) :367-381

[5] New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors [J].

Chopra, I .

DRUG RESISTANCE UPDATES, 2002, 5 (3-4) :119-125

[6] GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae:: preliminary guidelines and interpretive criteria [J].

Deshpande, LM ;

Gales, AC ;

Jones, RN .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (01) :29-35

[7] Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L-pneumophila pneumonia [J].

Edelstein, PH ;

Weiss, WJ ;

Edelstein, MAC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (02) :533-540

[8]

Edlund C, 2000, CLIN MICROBIOL INFEC, V6, P158

[9] AGE AND THE PHARMACOKINETICS OF ANGIOTENSIN CONVERTING ENZYME-INHIBITORS ENALAPRIL AND ENALAPRILAT [J].

HOCKINGS, N ;

AJAYI, AA ;

REID, JL .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (04) :341-348

[10] Disk diffusion susceptibility test development for the new glycylcycline, GAR-936 [J].

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1999, 35 (03) :249-252